SPRC Stock Overview
A clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SciSparc Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$6.78 |
| 52 Week Low | US$0.20 |
| Beta | 1 |
| 1 Month Change | -10.59% |
| 3 Month Change | -18.87% |
| 1 Year Change | -95.58% |
| 3 Year Change | -99.88% |
| 5 Year Change | n/a |
| Change since IPO | -99.82% |
Recent News & Updates
Shareholder Returns
| SPRC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -16.6% | -2.0% | -3.5% |
| 1Y | -95.6% | 7.6% | 22.1% |
Return vs Industry: SPRC underperformed the US Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: SPRC underperformed the US Market which returned 24% over the past year.
Price Volatility
| SPRC volatility | |
|---|---|
| SPRC Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SPRC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SPRC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Oz Adler | scisparc.com |
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form.
SciSparc Ltd. Fundamentals Summary
| SPRC fundamental statistics | |
|---|---|
| Market cap | US$749.50k |
| Earnings (TTM) | -US$5.68m |
| Revenue (TTM) | US$1.75m |
0.4x
P/S Ratio-0.1x
P/E RatioIs SPRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRC income statement (TTM) | |
|---|---|
| Revenue | US$1.75m |
| Cost of Revenue | US$541.00k |
| Gross Profit | US$1.21m |
| Other Expenses | US$6.89m |
| Earnings | -US$5.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.59 |
| Gross Margin | 69.03% |
| Net Profit Margin | -325.36% |
| Debt/Equity Ratio | 0% |
How did SPRC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 03:44 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SciSparc Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Piriyapon Kongvanich | Bualuang Securities PCL |
| Maxim Jacobs | Edison Investment Research |